Antares pharma announces divestiture of otrexup®

Ewing, n.j., dec. 15, 2021 (globe newswire) -- antares pharma, inc. (nasdaq: atrs) (the “company”), a specialty pharmaceutical company, today announced the divestiture of otrexup® (methotrexate) injection for the treatment of rheumatoid arthritis to a subsidiary of assertio holdings, inc., a commercial pharmaceutical company, for a total cash consideration of $44.0 million inclusive of otrexup® wip and finished inventory. under the terms of the asset purchase agreement, antares will receive an initial payment of $18.0 million at closing plus two additional time-based payments totalling $26.0 million in 2022.
ATRS Ratings Summary
ATRS Quant Ranking